KR20110124364A - Ｄｋｋ-１ 항체 - Google Patents

Ｄｋｋ-１ 항체 Download PDF

Info

Publication number
KR20110124364A
KR20110124364A KR1020117023571A KR20117023571A KR20110124364A KR 20110124364 A KR20110124364 A KR 20110124364A KR 1020117023571 A KR1020117023571 A KR 1020117023571A KR 20117023571 A KR20117023571 A KR 20117023571A KR 20110124364 A KR20110124364 A KR 20110124364A
Authority
KR
South Korea
Prior art keywords
seq
ser
gly
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117023571A
Other languages
English (en)
Korean (ko)
Inventor
마르시오 체디드
리안 제임스 달링
레이첼 쟈넷 갈빈
바바라 앤 스완슨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20110124364A publication Critical patent/KR20110124364A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117023571A 2009-04-10 2010-04-06 Ｄｋｋ-１ 항체 Ceased KR20110124364A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
US61/168,411 2009-04-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147005305A Division KR101461362B1 (ko) 2009-04-10 2010-04-06 Ｄｋｋ-１ 항체

Publications (1)

Publication Number Publication Date
KR20110124364A true KR20110124364A (ko) 2011-11-16

Family

ID=42199718

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020117023571A Ceased KR20110124364A (ko) 2009-04-10 2010-04-06 Ｄｋｋ-１ 항체
KR1020147005305A Active KR101461362B1 (ko) 2009-04-10 2010-04-06 Ｄｋｋ-１ 항체
KR1020147018130A Ceased KR20140090273A (ko) 2009-04-10 2010-04-06 Ｄｋｋ-１ 항체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020147005305A Active KR101461362B1 (ko) 2009-04-10 2010-04-06 Ｄｋｋ-１ 항체
KR1020147018130A Ceased KR20140090273A (ko) 2009-04-10 2010-04-06 Ｄｋｋ-１ 항체

Country Status (30)

Country Link
US (1) US8148498B2 (https=)
EP (3) EP2417158B9 (https=)
JP (1) JP5759977B2 (https=)
KR (3) KR20110124364A (https=)
CN (1) CN102388065B (https=)
AR (1) AR075989A1 (https=)
AU (1) AU2010234611B2 (https=)
BR (1) BRPI1014157B1 (https=)
CA (1) CA2758252C (https=)
CY (3) CY1119399T1 (https=)
DK (3) DK2930184T3 (https=)
EA (1) EA021401B1 (https=)
ES (3) ES2887176T3 (https=)
HR (3) HRP20171400T1 (https=)
HU (3) HUE055376T2 (https=)
IL (1) IL214845A (https=)
LT (3) LT2930184T (https=)
ME (2) ME02798B (https=)
MX (1) MX2011010707A (https=)
NZ (1) NZ595011A (https=)
PL (3) PL2930184T3 (https=)
PT (3) PT2930184T (https=)
RS (3) RS58612B1 (https=)
SG (1) SG175244A1 (https=)
SI (3) SI2930184T1 (https=)
TR (1) TR201907261T4 (https=)
TW (1) TWI546079B (https=)
UA (1) UA103916C2 (https=)
WO (1) WO2010117980A1 (https=)
ZA (1) ZA201107256B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220070117A (ko) * 2020-11-20 2022-05-30 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120475A1 (es) 2009-05-12 2012-05-05 Pfizer Anticuerpos especificos para dkk-1
CN111961134B (zh) 2012-12-10 2024-04-05 比奥根Ma公司 抗血液树突细胞抗原2抗体及其用途
AU2016263030A1 (en) * 2015-05-18 2017-10-12 Eli Lilly And Company Anti-Dkk-1-anti-RANKL bispecific antibody compounds
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
KR102701695B1 (ko) 2016-10-26 2024-08-30 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
AU2019301160A1 (en) * 2018-07-11 2021-02-25 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CTLA-4
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
BR112022004851A2 (pt) * 2019-09-19 2022-08-23 Leap Therapeutics Inc Uso de inibidores de dkk-1 para tratar câncer
EP4061419A1 (en) 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
IL304927A (en) * 2021-02-05 2023-10-01 Omeros Corp A biomarker for assessing the risk of developing acute COVID-19 and post-acute COVID-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
EP4471056A4 (en) * 2022-01-28 2026-02-18 Shanghai Junshi Biosciences Co Ltd Anti-DKK1 antibodies, pharmaceutical composition and associated uses
KR20250057775A (ko) 2022-07-12 2025-04-29 리프 테라퓨틱스 인코포레이티드 조합 요법
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU7137398A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IL158750A0 (en) 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
JP2005512557A (ja) 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
EP1636388A2 (en) 2003-06-06 2006-03-22 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101641373B (zh) * 2007-02-08 2015-02-11 默沙东公司 Dkk-1的特异性抗体
CN102421798A (zh) * 2009-05-07 2012-04-18 诺瓦提斯公司 与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220070117A (ko) * 2020-11-20 2022-05-30 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도

Also Published As

Publication number Publication date
SG175244A1 (en) 2011-12-29
EP3514173B8 (en) 2021-08-04
CY1119399T1 (el) 2018-02-14
CA2758252C (en) 2015-02-24
KR20140090273A (ko) 2014-07-16
HUE043904T2 (hu) 2019-09-30
PL2417158T3 (pl) 2017-12-29
PT2930184T (pt) 2019-06-17
RS62214B1 (sr) 2021-09-30
RS56505B1 (sr) 2018-02-28
CY1121637T1 (el) 2020-07-31
TR201907261T4 (tr) 2019-06-21
HUE034625T2 (en) 2018-02-28
EP2417158B9 (en) 2017-12-06
HUE055376T2 (hu) 2021-11-29
JP5759977B2 (ja) 2015-08-05
DK2930184T3 (da) 2019-05-13
ME03378B (me) 2020-01-20
SI2930184T1 (sl) 2019-06-28
WO2010117980A1 (en) 2010-10-14
UA103916C2 (xx) 2013-12-10
LT3514173T (lt) 2021-09-10
HRP20190643T1 (hr) 2019-05-31
KR20140033523A (ko) 2014-03-18
LT2930184T (lt) 2019-05-10
KR101461362B1 (ko) 2014-11-13
CN102388065B (zh) 2014-09-03
CA2758252A1 (en) 2010-10-14
PT2417158T (pt) 2017-10-23
ES2644244T3 (es) 2017-11-28
EA201171237A1 (ru) 2012-04-30
HRP20171400T1 (hr) 2017-11-03
SI2417158T1 (sl) 2017-10-30
DK2417158T3 (en) 2017-10-16
BRPI1014157A2 (pt) 2020-09-29
TWI546079B (zh) 2016-08-21
EP3514173B1 (en) 2021-06-23
AU2010234611B2 (en) 2013-02-07
US8148498B2 (en) 2012-04-03
EP3514173A1 (en) 2019-07-24
RS58612B1 (sr) 2019-05-31
US20100260754A1 (en) 2010-10-14
DK3514173T3 (da) 2021-08-02
ZA201107256B (en) 2013-03-27
AU2010234611A1 (en) 2011-10-20
IL214845A (en) 2016-06-30
EA021401B1 (ru) 2015-06-30
ES2887176T3 (es) 2021-12-22
EP2417158A1 (en) 2012-02-15
CN102388065A (zh) 2012-03-21
ME02798B (me) 2018-01-20
EP2417158B1 (en) 2017-08-02
IL214845A0 (en) 2011-11-30
ES2728911T3 (es) 2019-10-29
HRP20211343T1 (hr) 2021-11-26
CY1124412T1 (el) 2022-07-22
MX2011010707A (es) 2012-02-28
PT3514173T (pt) 2021-08-16
PL2930184T3 (pl) 2019-10-31
DK2417158T4 (da) 2018-01-29
JP2012523417A (ja) 2012-10-04
NZ595011A (en) 2013-05-31
PL3514173T3 (pl) 2022-01-17
AR075989A1 (es) 2011-05-11
LT2417158T (lt) 2017-10-10
SI3514173T1 (sl) 2021-09-30
TW201100101A (en) 2011-01-01
EP2930184B1 (en) 2019-03-27
EP2930184A1 (en) 2015-10-14
BRPI1014157B1 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
KR101461362B1 (ko) Ｄｋｋ-１ 항체
AU2018201333B2 (en) DKK1 Antibodies And Methods Of Use
KR102184343B1 (ko) 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
JP6430438B2 (ja) 網膜神経線維層変性の治療に使用するためのｒｇｍ ａタンパク質に対するモノクローナル抗体
AU2009311375A1 (en) Anti-TGF-beta receptor II antibodies
AU2007253586A1 (en) High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity
CN114945593B (zh) 抗IL-1β抗体
TW202323290A (zh) 涉及il-18抗體之方法及治療
HK1162183A (en) Dkk-1 antibodies
HK1162183B (en) Dkk-1 antibodies

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20111007

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111007

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130422

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130422

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140227

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20140228

WITB Written withdrawal of application